The U.S. National Cancer Institute (NCI) awarded a $642,755 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Institute for Cancer Research, a non-profit subsidiary of Temple University. The funding supports research to target the phospholipid scramblase Anoctamin 6 (ANO6) expressed in cancer-associated fibroblasts (CAFs) within pancreatic ductal adenocarcinoma (PDAC) tumors. The research aims to disrupt the trogocytosis (membrane transfer) process by which CAFs feed lipids to PDAC tumor cells, as well as investigate how blocking ANO6 can enhance anti-tumor immunity by increasing the efficacy of immunotherapies. The 5-year project runs from March 2025 to February 2030 and involves a multidisciplinary team of experts in cancer biology, lipid metabolism, calcium signaling, and tumor immunology. The goal is to develop ANO6 as a therapeutic target to improve outcomes for patients with this intractable malignancy.
Generated 4/1/25, 1:49 AM